SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Sharck Soup
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Sharck who started this subject5/17/2001 12:31:36 PM
From: besttrader  Read Replies (1) of 37746
 
Myriad Genetics (MYGN) 61.30 +1.24: Friedman Billings initiates coverage with a BUY and a price target of $71; says MYGN's diagnostic, target validation and protein pathway elucidation technologies are some of the best in the industry; believes that MYGN, with its deep belief in, and understanding of, proteomics, holds up perhaps the highest bar for its prospective drug targets to hurdle.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News